Multiple fixed doses of 'seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo

Biological Psychiatry

Volumn 42, Issue 4, 1997, Pages 233-246

  Arvanitis, Lisa A ^a   Miller, Barbara G ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

5 HT2 antagonist; antipsychotic; ICI 204,636; quetiapine; schizophrenia; seroquel

Indexed keywords

HALOPERIDOL; PLACEBO; PROLACTIN; QUETIAPINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; VERTIGO;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030795988     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00190-X     Document Type: Article

References (22)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington, DC: American Psychiatric Press.
2. Andreasen N (1984): Modified Scale for the Assessment of Negative Symptoms. NIMH Treatment Strategies in Schizophrenia Study. Washington, DC: Department of Health and Human Services, Public Health Administration. Publication ADM 9-102.
3. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, and the Olanzapine HGAD Study Group (1996): Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
4. Borison RL, Arvanitis LA, Miller BG, and the US SEROQUEL Study Group (1996): ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16:158-169.
5. Ellenbrock BA, Lubbers LJ, Cools AR (1996): The activity of 'Seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine. Neuropsychopharmacology 15:406-416.
6. Everitt BS (1992): The Analysis of Contingency Tables, 2nd ed. London: Chapman & Hall.
7. Fabre LF, Arvanitis LA, Pultz J, Jones VM, Malick JB, Slotnick VB (1995): ICI 204,636, a novel atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 17:366-378.
8. Goldstein JM (1995): Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Expert Opin Invest Drugs 4:291-298.
9. Goldstein JM, Arvanitis LA (1995): ICI 204,636 (SEROQUEL™): A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Rev 1:50-73.
10. Guy W (ed) (1976): ECDEU Assessment Manual for Psychopharmacology, rev ed. Rockville, MD: US Department of Health, Education, and Welfare. Publication ADM 76-338.
11. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
12. Migler BM, Litwin LC, Sutton EB, Malick JB (1993): Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112:293-307.
13. Overall JE, Gorham DR (1962): The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
14. Peuskens J for the Risperidone Study Group (1995): Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726.
15. Robertson GS, Matsumura H, Fibiger HC (1994): Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. Pharmacol Biochem Behav 271:1058-1066.
16. Roy-Byrne PP, Joffe RT, Uhde TW, Post RM (1984): Carbemazepine and thyroid function in affectively ill patients: Clinical and theoretical implications. Arch Gen Psychiatry 41:1150-1153.
17. Saller CF, Salama AL (1993): Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112: 285-292.
18. Simpson GM, Angus JW (1970): A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19.
19. Smith PJ, Surks MI (1984): Multiple effects of 5,5prime;-diphenylhydantoin on the thyroid hormone system. Endocr Rev 5:514-524.
20. Surks MI, Sievert R (1995): Drugs and thyroid function. N Engl J Med 333:514-524.
21. Tukey JW, Ciminera JL, Heysee JF (1985): Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41:295-301.
22. Van Putten T, Marder SM, Mintz J (1990): A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47:754-758.